EGFR and hepatocellular carcinoma: In order to further ascertain the effect of DBF4 on HCC cells through the ERBB pathway, we subjected a part of Huh7 cells overexpressing DBF4 to treatment with the ERBB inhibitor dacomitinib for 24 h.